 BOSTON, Feb. 22, 2022 PRNewswire -- Stealth BioTherapeutics Corp Nasdaq:MITO, a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the virtual Mitochondria-Targeted Drug Development Summit on Thursday, February 24, 2022 at 9:00 a.m. ET. Reenie McCarthys presentation is titled, Mitochondria as a Target for Ophthalmic Disease, which will focus on mitochondrial dysfunction as a key pathology in ophthalmic conditions such as dry age-related macular degeneration AMD, glaucoma, diabetic retinopathy and Fuchs corneal endothelial dystrophy. 